FDA Warning Letter to BMC Medical Co., Ltd. (2026-05-20) — CGMP/QSR/Medical Devices/PMA/Adulterated/Misbranded
Letter issued · posted to fda.gov .
Subject as published: CGMP/QSR/Medical Devices/PMA/Adulterated/Misbranded
TL;DR
In short: **FDA Warning Letter to BMC Medical Co., Ltd. (CMS # 725759, May 20, 2026)** The FDA's Center for Devices and Radiological Health cited BMC Medical Co., Ltd. as the specification developer and 510(k) owner of G3X APAP ventilator devices (Model LG3600) imported by 3B Medical, Inc. (Dublin, OH), finding the devices adulterated and misbranded because BMC made significant design changes—including firmware updates with new detection algorithms for hypopnea classification, modifications to the sound abatement system, and a new PCBA chip with updated master control software—without submitting a required 510(k) premarket notification as mandated by 21 CFR 807.81(a)(3). The FDA determined these modifications could significantly affect device safety and effectiveness and requested that BMC cease activities resulting in misbranding or adulteration.
Argus analysis
# FDA Warning Letter Analysis: BMC Medical Co., Ltd.
**Company and Findings**
BMC Medical Co., Ltd., a Beijing-based specification developer and 510(k) owner, received a warning letter from FDA's Center for Devices and Radiological Health on May 20, 2026 (CMS #725759). The agency conducted an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) in Dublin, Ohio from December 1–10, 2025, and determined that BMC is the design authority for Auto-CPAP ventilator devices sold under the G3X APAP brand. These devices treat obstructive sleep apnea in adults but were found to violate federal law governing medical device marketing and safety reporting.
**Regulatory Citations and Violations**
FDA cited violations of 21 CFR 807.81(a)(3) and sections 501(f)(1)(B) and 502(o) of the Federal Food, Drug, and Cosmetic Act. The agency found that BMC made significant design changes—including firmware updates with new respiratory event detection algorithms, sound abatement system modifications, and a new circuit board chip—without submitting a required 510(k) premarket notification. These changes could affect device safety and effectiveness. Additionally, BMC violated 21 CFR Part 806 and section 519 of the FD&C Act by failing to report a firmware correction within the required 10-day window after discovering that firmware version G3-2.00.76 caused unexpected device shutdowns during patient therapy.
**Response Timeline and Industry Observations**
BMC must submit a written response within 15 business days detailing corrective actions, including documentation and implementation timelines if work extends beyond that period. Peer compliance officers in respiratory device manufacturing should monitor whether BMC submits the delinquent correction report, files a new 510(k) for the G3X APAP design changes, and implements updates to design change evaluation procedures. Any compliance response should reference the FDA's updated Quality Management System Regulation (effective February 2, 2026) for CGMP-related corrections.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER BMC Medical Co., Ltd. MARCS-CMS 725759 — May 20, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Medical Devices Recipient: Recipient Name Jian Xu Recipient Title President BMC Medical Co., Ltd. No. 16 Lize Road Room 10, 17F Building 4, Huiya Plaza Fengtai Qu Beijing Shi , 100073 China (b)(6) Issuing Office: Center for Devices and Radiological Health United States WARNING LETTER CMS # 725759 May 20, 2026 Dear Mr. Xu: During an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. Unapproved Device Violations Our inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/default.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed. Your firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "high" severity rating mean for this letter?
- High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has BMC Medical Co., Ltd. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for BMC Medical Co., Ltd. as of 2026-06-30. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Warning Letter to BMC Medical Co., Ltd. (2026-05-20) — CGMP/QSR/Medical Devices/PMA/Adulterated/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-bmc-medical-co-ltd-2026-05-20-cgmp
"FDA Warning Letter to BMC Medical Co., Ltd. (2026-05-20) — CGMP/QSR/Medical Devices/PMA/Adulterated/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-bmc-medical-co-ltd-2026-05-20-cgmp.
Argus HQ Research. "FDA Warning Letter to BMC Medical Co., Ltd. (2026-05-20) — CGMP/QSR/Medical Devices/PMA/Adulterated/Misbranded." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-bmc-medical-co-ltd-2026-05-20-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_bmc_medical_co_ltd_2026_05_20_cgmp_2026,
title = {FDA Warning Letter to BMC Medical Co., Ltd. (2026-05-20) — CGMP/QSR/Medical Devices/PMA/Adulterated/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-bmc-medical-co-ltd-2026-05-20-cgmp},
note = {Accessed: July 13, 2026}
}